Schizophrenia is a severe psychiatric illness affecting almost 25 million people worldwide
and is conceptualized as a disorder of synaptic plasticity and brain connectivity …

Treatment resistant schizophrenia (TRS) is characterized by a lack of, or suboptimal
response to, antipsychotic agents. The biological underpinnings of this clinical condition are …

Dysfunctions of the dopaminergic system are believed to play a major role in the core
symptoms of schizophrenia such as positive, negative, and cognitive symptoms. The first line …

Antipsychotics represent the mainstay of schizophrenia pharmacological therapy, and their
role has been expanded in the last years to mood disorders treatment. Although introduced …

Therapeutic intervention for schizophrenia relies on blockade of dopamine D2 receptors in
the associative striatum; however, there is little evidence for baseline overdrive of the …

Schizophrenia has been primarily associated with dopamine dysfunction, and treatments
have been developed that target the dopamine pathway in the central nervous system …

Schizophrenia is a disease with a complex pathological mechanism that is influenced by
multiple genes. The study of its pathogenesis is dominated by the dopamine hypothesis, as …

Treatment of schizophrenia (SCZ) historically relies on the use of antipsychotic drugs to treat
psychosis, with all of the currently available antipsychotics acting through the antagonism of …

Dopamine receptors are widely distributed within the brain where they play critical
modulator roles on motor functions, motivation and drive, as well as cognition. The …

Schizophrenia is a chronic and debilitating neuropsychiatric disorder affecting
approximately 1% of the world's population. This disease is associated with considerable …